AKSO Biopharmaceutical is a global focused biopharmaceutical company dedicated to delivering groundbreaking therapeutics for patients with urgent unmet clinical needs in cancer, fibrosis and autoimmune diseases.

Transforming the Future of Protein Therapeutics by harnessing the full potential of \u0003protein-protein interaction. We work to integrate our engineering strategies with a deep understanding in disease driven biological pathways, to develop and deliver a growing portfolio of novel and best-in-class protein therapeutics.

Directed Evolution Enhancement Platform utilizes strategic marriage of knowledge between biochemical and structural information aiming at fully leveraging the natural component of any given target system. Result in effective blocking and activation of any protein-protein interaction.

AKSO and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize AB002 in Asia Pacific Ex-Japan. February 19, 2022

Apr 19, 2021 · Dr. Zhang is the Co-Founder and Chief Executive Officer of AKSO Biopharmaceutical, Inc. He brings extensive expertise in corporate finance, strategic planning, and operational management to the company.

AKSO Biopharmaceutical - 1801 Century Park East, Ste 1901, Los Angeles, CA 90067

Feb 19, 2022 · Huadong Medicine is granted from AKSO Biopharmaceutical an exclusive right to develop and commercialize AB002 in the Asia Pacific Ex-Japan region for solid tumors; AKSO Biopharmaceutical to receive up to 75 million USD upfront, R&D funding, potential regulatory and commercial milestone payments

Dr. Miao is co-founder and Chief Scientific Advisor of AKSO Biopharmaceutical Inc. Prior to founding AKSO Bio, Dr. Miao led the development effort of numerous therapeutic molecules that are currently in clinical trials. She received her doctorate …

Mr. Zhang is co‐founder and Chief Executive Officer of AKSO Biopharmaceutical Inc. Mr. Zhang brings a wealth of corporate finance, strategic and operation management experience to AKSO.

Dr. Giaccia is the Co-Founder, Senior Scientific Strategist, and Chairman of AKSO Biopharmaceutical, Inc. He currently serves as the Director of the Oxford Institute of Radiation Oncology in the UK and holds the title of Jack, Lulu, and Sam Wilson Professor Emeritus of Radiation Oncology at Stanford University School of Medicine.